Caricamento...
Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central...
Salvato in:
| Pubblicato in: | Brain Sci |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7692182/ https://ncbi.nlm.nih.gov/pubmed/33143271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/brainsci10110802 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|